Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Adjuvant Study of GRANITE-001 in High-Risk Localized Tumors

Trial Profile

A Phase II Adjuvant Study of GRANITE-001 in High-Risk Localized Tumors

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GRANITE 001 (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
  • Focus Therapeutic Use
  • Sponsors Gritstone bio

Most Recent Events

  • 05 Aug 2021 According to a Gritstone bio media release, the company expects to initiate this study in the first half of 2022.
  • 06 May 2021 According to a Gritstone bio media release, the company expects to initiate this study in the second half of 2021.
  • 24 Jun 2020 According to a Gritstone Oncology media release, the company announced that the company will host an investor teleconference and webcast on July 13, 2020 at 8:00 a.m. ET where phase 2 study plans will also be discussed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top